Belite Bio Doses First Patient In Phase 2/3 DRAGON II Trial At Tokyo Medical Center For Tinlarebant, An Oral Therapy Targeting STGD1 Retinal Disease; Study To Evaluate Efficacy And Safety In 60 Adolescent Patients Across The U.S., U.K., And Japan
Portfolio Pulse from Benzinga Newsdesk
Belite Bio has dosed the first patient in its Phase 2/3 DRAGON II trial for Tinlarebant, targeting STGD1 retinal disease. The trial will assess efficacy and safety in 60 adolescent patients across the U.S., U.K., and Japan. Tinlarebant has received Orphan Drug and Sakigake Designation in Japan.
September 10, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio has initiated a Phase 2/3 trial for Tinlarebant, targeting STGD1 retinal disease, with 60 patients across multiple countries. The drug has received Orphan Drug and Sakigake Designation in Japan, indicating potential regulatory support.
The initiation of the Phase 2/3 trial for Tinlarebant is a significant step for Belite Bio, as it targets a specific retinal disease (STGD1). The Orphan Drug and Sakigake Designation in Japan suggest potential regulatory advantages, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100